Given the high expression of PSMA on the majority of prostate cancers, the availability of high-affinity PSMA-targeted probes, labelled with therapeutic radioisotopes, offers promising perspectives for PSMA-targeted endoradiotherapy. Here, FOLH1 is linked to prostate cancer.